Even though there have been plenty of changes in the health care industry, pharma CEOs have remained largely unaffected as turnover in the industry is well below that of other sectors.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

{In Vivo} summarizes the technologies of several medical companies founded recently, including Belgium's [AlgoNomics NV], a new entrant in the biocomputing and bioinformatics arena. [CoPharma Inc.]'s mission is to develop drug and biological products through joint ventures with discovery firms. Launched in February 2000 with $2 million from Sanderling, Alta Partners and Graystone, [Cythera Inc.] will develop therapies based on the transplantation of functional human cells grown{ in vitro}, offering an alternative to the use of donated human tissues. [Embolic Protection Inc.] has developed a device, consisting of a guide wire and filter mechanism, to remove embolic debris. Denmark's [NsGene A/S] is a joint venture of NeuroSearch A/S and the University of Lund. [WebEBM] will offer evidence-based clinical guidelines for 400 diseases or conditions on its website.